Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 26;10(5):684. doi: 10.3390/vaccines10050684

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

rAb ZH9F7-Cap targets skin cDC1 s and cDC2s/LCs in vivo. (a) Skin migratory CD163^−/lowCD172a^+/− cells were selected and analyzed for CADM1 expression, obtaining skin cDC1 (CD163⁻CADM1⁺CD172a^−/low) and cDC2/LC (CD163^−/lowCADM1⁺CD172a^high) cells. (b) Skin cDC1, cDC2/LC, and moDCs/Macro positive for targeting in vivo. The dot plot represents results from one of three experimental units from the control, rAb ZH9F7-Cap, and rAb 7DEU-Cap. (c) Average percentages of cDC1, cDC2/LC, and moDCs/Macro positive from in vivo targeting from three groups. PBS control (gray); rAb ZH9F7-Cap (blue); Isotype control rAb 7DEU-Cap (black). One-way ANOVA and the Tukey–Kramer test for multiple comparisons of means were performed (p < 0.05). p-values denote statistically significant differences in the means of the different groups.